Latest / GeriPal - A Geriatrics and Palliative Medicine Podcast
All things Amyloid, including Aducanumab and Amyloid PET scans with Gil Rabinovici
There are no currently approved disease modifying drugs for Alzheimer's disease, but in a couple months that may change. In July of 2021, the FDA will consider approval of a human monoclonal antibody called Aducanumab for the treatment of Alzheimer's disease. If approved, it will not only make this drug the defacto standard of care for Alzheimer's disease, but will create a monumental shift in the usage of other currently limited diagnostic tests, including Amyloid PET scans and other biomarkers.
On today's podcast, we talk about all things Amyloid, including Aducanumab and Amyloid PET scans…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.